EUR 5.6 million will be spent on new research project SafePolyMed in Europe. Scientists from Germany, Estonia, Finland, Greece, Slovenia and the Netherlands intend to develop a web-based system within 3.5 years that doctors, pharmacists and patients can use to individually assess the risk of adverse reactions when taking multiple medicines.
The international research project SafePolyMed has started in Europe. Within the framework of the EU program for research and innovation Horizon Europe (2021-2027), over 5.6 million euros were allocated for it. The goal of the project is to create a service for doctors, pharmaceutical specialists and patients using machine learning and artificial intelligence technologies to individually assess the risk of adverse reactions when taking several medicines, reports Deutsche Apotheker Zeitung.
According to the European Commission, about 197,000 deaths a year in Europe are due to adverse medicines reactions. Preventing these losses is one of the goals of the new project. When assessing the risks, not only the interaction of the active substances of various medicines, but also the genetic characteristics of the patient will be taken into account.
“The key goal of the project is to improve clinical decision-making by using powerful genetic risk information with drug data to better predict treatment response and appropriate patient stratification,” says Professor Samuli Ripatti from the Finnish Institute of Molecular Medicine at the University of Helsinki.
The safety of drugs is closely related to the dosing regimen, so the project participants will separately study the issue of dose adjustment taking into account the individual characteristics of the patient. To do this, they plan to use mathematical modeling.
As a final result, SafePolyMed will provide a prototype of a user-friendly, web-based clinical decision support system.
